Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ribociclib plus adjuvant endocrine therapy in high-risk early HR-positive/HER2-negative breast cancer
MOH_2017-08-30_000556Phase 3Not yet recruiting
- Sponsor
- Novartis
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Ribociclib + standard endocrine therapy with Placebo + standard endocrine therapy (2 arms). Primary endpoint: Invasive disease-free survival. Planned start May 2017; status: not yet recruiting.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2017-08-30_000556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-08-30_000556.